Insider trade

Director sold ~$48K of HALO shares in the open market

Traded Jul 1, 2026 · Filed Jul 2, 2026

Why it stands out

A board member of Halozyme sold $48K of Halozyme shares. It was planned long ago, so it says very little.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Director$25K–$100KPre-arranged plan referenced

Classification

open market sale

Code S — open-market or private sale

Absolute commitment

~$48,256

Shares × reported transaction price

Timing vs results

51 days after results of May 11, 2026, 36 days before results of Aug 6, 2026

Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results

Planned / mechanical clue

Footnote references a pre-arranged trading plan (Rule 10b5-1)

Only flagged when a footnote says so; never inferred

After	Stock	S&P 500	Difference
7 days	−5.8%	−0.3%	−5.5%
30 days	+3.5%	+2.5%	+1.0%
90 days	+34.1%	+3.1%	+30.9%

Past results only. Not a forecast.

The sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on May 29, 2025 in accordance with Rule 10b5-1.
Represents a weighted average sales price per share. The shares were sold at prices ranging from $76.950 to $77.710. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

3mo ago

Derivative exercise or conversion — not an open-market buy.

Scheduled in advance3mo ago

Scheduled in advance3mo ago